NCT03333343 2026-01-16Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCNovartisPhase 1 Active not recruiting105 enrolled
NCT03742349 2025-05-18Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).NovartisPhase 1 Terminated64 enrolled